Antibiotic distribution and recovery in tissue
Project factsheets
The Innovative Health Initiative builds on the successes of the Innovative Medicines Initiative (IMI), which launched over 180 projects. Many IMI projects are still ongoing and are monitored by the IHI Programme Office. This section features the factsheets of all IMI projects. Once IHI projects are up and running, we will also promote them here.
Displaying 23 projects/programmes
Antimicrobial Resistance Accelerator
Corona accelerated R&D in Europe
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen: phase II
Bringing a prophylactic Ebola vaccine to licensure
European prevention of Alzheimer’s dementia consortium
Novel Gram-negative antibiotic now
Inhaled antibiotics in bronchiectasis and cystic fibrosis
Development of Impentri, an intravenous imatinib formulation for COVID-19 acute respiratory distress syndrome (ARDS)
Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA
New Drugs for Bad Bugs
Parkinson disease with mild cognition impairment treated with nicotinic agonist drug
PERtussIS COrrelates of Protection Europe
Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases
Proton versus photon therapy for esophageal cancer - a trimodality strategy
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Saracatinib trial to prevent FOP
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments
Academia and industry united innovation and treatment for tuberculosis
